|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 157.14 USD | -2.87% |
|
-6.66% | -13.96% |
| 10-14 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 10-08 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 8,475 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | -7.96% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 8,327 | 8,054 | 7,588 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | -8.21% | -3.28% | -5.79% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -56x | 39.4x | 14.7x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 131x | 22.7x | 7.63x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.6x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 8.9x | 5.58x | 3.97x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 8.74x | 5.3x | 3.56x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -59.8x | 41.1x | 17.2x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -56.1x | 32.9x | 10.8x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -158x | 22.6x | 11.3x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.63% | 4.43% | 8.84% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.888 | 4.109 | 11.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 952.6 | 1,519 | 2,134 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -139.3 | 195.7 | 440.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -148.5 | 245.1 | 702.2 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -152 | 221.7 | 626.7 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -147.6 | -421 | -887 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 161.79 | 161.79 | 161.79 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,381 | - | - |
| Announcement Date | 01/03/22 | 27/02/23 | 20/02/24 | 18/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -56.02x | 8.74x | -59.77x | -.--% | 8.47B | |
| 35.8x | 12.9x | 27.02x | 0.55% | 1,116B | |
| 37.07x | 6.25x | 17.38x | 2.11% | 610B | |
| 36.17x | 8.31x | 17.13x | 2.45% | 501B | |
| 112.15x | 5.92x | 25.35x | 2.35% | 358B | |
| 20.49x | 5x | 12.4x | 2.64% | 366B | |
| 21.24x | 5.55x | 13.66x | 2.88% | 288B | |
| 22x | 4.43x | 12.71x | 1.99% | 261B | |
| 27.56x | 7.08x | 12.68x | 2.32% | 235B | |
| -45.98x | 7.04x | 27.26x | 2.1% | 195B | |
| Average | 21.05x | 7.12x | 10.58x | 1.94% | 393.82B | |
| Weighted average by Cap. | 34.85x | 8.17x | 19.80x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
